EJNMMI Research

Table 3 Average TBF and [¹⁸F]FLT V_T values of all the lesions as assessed at the three time points: baseline, 7 days post-therapy and 28 days post-therapy

From: Validation of [¹⁸F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor

	Baseline	7 days post-therapy	28 days post-therapy
Patients	TBF
1	0.46	0.40	0.44
2	0.60	0.85	0.86
3	0.47	0.58	0.39
4	0.54	0.58	0.82
5	0.32	–*	0.27
6	0.49	0.35	0.32
Patients	[¹⁸F]FLT V_T
1	5.69	3.63	3.21
2	4.89	2.75	3.30
3	7.62	2.83	3.21
4	4.75	3.71	3.20
5	5.02	4.17	3.26
6	4.20	2.70	2.54

*TBF data for patient 5 was unavailable

Back to article page